Fecal Transplants More Successful from “Super-Donors”

A review finds that for several conditions, poop from certain healthy people is more likely to provide relief for recipients.

Written byShawna Williams
| 2 min read
an illustration of the human gut with bacteria inside

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: © ISTOCK.COM, GREENVECTOR

Not all poop is equally valuable, at least when it comes to fecal transplants. Some people, it appears, generate waste that is better at alleviating conditions associated with gut microbiome imbalances than others, according to a review article published yesterday (January 21) in Frontiers in Cellular and Infection Microbiology.

“Strategies to find super-donors whose stool is especially effective as a curative are still in their infancy, although progress on this topic—or making synthetic super-donors from the stool of many people—could greatly improve application of [faecal transplants],” Rob Knight, a microbiology researcher at the University of California, San Diego, who wasn’t involved in the review, tells The Guardian.

The authors of the paper looked at studies on the use of fecal microbiota transplants (FMT) to treat Clostridium difficile infection, inflammatory bowel disease, constipation, allergic colitis, and other conditions. They write in their conclusion that the existence of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Shawna was an editor at The Scientist from 2017 through 2022. She holds a bachelor’s degree in biochemistry from Colorado College and a graduate certificate in science communication from the University of California, Santa Cruz. Previously, she worked as a freelance editor and writer, and in the communications offices of several academic research institutions. As news director, Shawna assigned and edited news, opinion, and in-depth feature articles for the website on all aspects of the life sciences. She is based in central Washington State, and is a member of the Northwest Science Writers Association and the National Association of Science Writers.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies